Of 255 patients with known molecular subtype, the percentage of HER2-enriched and triple-negative subtype accounted for 50% of the IBCs, 19.38% of the cancers detected outside the screening program, 16.67% of the SBCs, and 12.2% of the NBCs (Fig. 2B). This evidence concerns the gene ERBB2 and cancer.